Characteristic | Antihypertensive | Antithrombotic | Antilipidemic | ||||||
---|---|---|---|---|---|---|---|---|---|
 | Not Persistenta | Unadj OR | Adj OR | Not Persistenta | Unadj OR | Adj OR | Not Persistenta | Unadj OR | Adj OR |
Stroke Cohort | 21/384 (5.5) | Â | Â | 20/405 (4.9) | Â | Â | 22/307 (7.2) | Â | Â |
Age (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   < 65 | 7/112 (6.3) | 0.42 (0.16, 1.13) | 0.37 (0.13, 1.03) | 9/130 (6.9) | 0.82 (0.29, 2.29) | 0.92 (0.32, 2.65) | Not significant |  |  |
   65–79 | 3/192 (1.6) | 0.10 (0.03, 0.37) | 0.11 (0.03, 0.39) | 4/191 (2.1) | 0.24 (0.07, 0.83) | 0.23 (0.06, 0.81) |  |  |  |
   ≥ 80 | 11/80 (13.8) | 1.00 | 1.00 | 7/84 (8.3) | 1.00 | 1.00 |  |  |  |
Total medications prescribedb | Â | 0.80 (0.65, 0.995) | Â | Not significant | Â | Â | Not significant | Â | Â |
Monthly drug costsc | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   < $90.00 | 7/78 (9.0) | 7.05 (1.43, 34.81) | 6.74 (1.32, 34.46) | Not significant |  |  | Not significant |  |  |
   $90.00 – $199.99 | 12/161 (7.5) | 5.76 (1.27, 26.18) | 5.25 (1.14, 24.25) |  |  |  |  |  |  |
   ≥ $200.00 | 2/145 (1.4) | 1.00 | 1.00 |  |  |  |  |  |  |
OHS impairment before stroke | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Independent | Not significant |  |  | 17/390 (4.4) | 1.00 | 1.00 | Not significant |  |  |
   Dependent |  |  |  | 3/15 (20.0) | 5.49 (1.41, 21.27) | 7.01 (1.66, 29.58) |  |  |  |
OHS impairment at discharge | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Independent | Not significant |  |  | 11/318 (3.5) | 1.00 |  | Not significant |  |  |
   Dependent |  |  |  | 9/87 (10.3) | 3.22 (1.29, 8.04) |  |  |  |  |
Tobacco use before stroke | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Yes | Not significant |  |  | Not significant |  |  | 5/23 (21.7) | 4.35 (1.44, 13.13) | 4.35 (1.44, 13.13) |
   No |  |  |  |  |  |  | 17/283 (6.0) | 1.00 | 1.00 |
History of previous stroke | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Yes | Not significant |  |  | Not significant |  |  | 1/76 (1.3) | 0.13 (0.02, 1.004) |  |
   No |  |  |  |  |  |  | 21/230 (9.1) | 1.00 |  |